Skip to main content

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Reports on New Research in Published Journal Article

DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, has published new research in the peer-reviewed journal, “Applied Sciences,” as part of a special issue featuring digital therapeutics applications for chronic disease management. The research shows improved outcomes for users living with diabetes across different racial and ethnic groups. According to the announcement, disparities among racial and ethnic groups are common in many chronic conditions, including diabetes. The research evaluated retrospective data from 1,000 individuals diagnosed with type 2 diabetes who used Dario’s platform during a 12-month period. Data from users who identified as White was compared to the data of those identifying as Black, Latino or Asian. The article reported that the gathered data indicated no statistical difference in the levels of engagement across racial and ethnic groups as well as notable improvements in average blood glucose between the first and last month with no statistical difference between racial and ethnic groups. Specifically, the numbers show a 14% reduction in White users and a 15% reduction in Black, Latino and Asian users. “We are thrilled to expand our research on the important topic of digital health as a means to help address health inequities,” said Dario vice president of clinical and scientific affairs Yifat Hershcovitz, PhD, in the press release. “We serve a diverse user population and improving outcomes for everyone is always our goal. This new study provides assurance that our solutions have a positive clinical impact regardless of race or ethnicity.”

To view the full press release, visit

About DarioHealth Corp.

DarioHealth Corp. is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.